Biofrontera Inc. (BFRIW) stock
Close on Oct 30, 2026Market cap $12.96MP/E –Yield –
Biofrontera Inc. grew revenue 17.8% to $46.18M over the twelve months to Jun 30, 2026. Free cash flow was -$7.93M. At the latest close the market valued the company at $12.96M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $12.96M
- P/E ratio
- –
- Price to sales
- 0.28
- Price to book
- 2.18
- Dividend yield
- –
- Free cash flow yield
- -61.17%
Fundamentals
- Revenue
- $46.18M
- Net income
- -$6.37M
- EPS, diluted
- -$0.60
- Free cash flow
- -$7.93M
- Book value per share
- $0.46
- Diluted shares
- 13M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $0.00
- Open
- $0.00
- Day's range
- $0.00 – $0.00
- Volume
- 37,967
- Average volume (20 days)
- 9,420
- Beta (5 years)
- 0.97
- 52-week range
- $0.55 – $1.66
- RSI (14 days)
- 42.4
- Volatility (1 year)
- 81.1%
- Relative volume
- 0.64×
- WACC
- 9.8%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | BFRIW | S&P 500 | Difference | BFRIW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -85.7% | -0.9% | −84.8 pts | ||
| 3 months | -95.3% | +2.1% | −97.5 pts | ||
| Year to date | -98.4% | +11.7% | −110.1 pts | ||
| 1 year | -99.0% | +12.4% | −111.4 pts | ||
| 3 years | -96.0% | +88.6% | −184.6 pts | -65.8% | +23.5% |
| 5 years | -99.9% | +75.9% | −175.8 pts | -74.5% | +12.0% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Biofrontera filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- Results
- Update
- News
About Biofrontera
Pharmaceutical Preparations
Biofrontera Inc. is a biopharmaceutical company that develops, manufactures, and commercializes pharmaceutical treatments for dermatological conditions, focusing on photodynamic therapy. Its primary product line comprises Ameluz, a prescription drug, and the RhodoLED series of illumination lamps, including BF-RhodoLED and RhodoLED XL. Together, these products are used to treat actinic keratosis, a pre-cancerous skin condition, on the face and scalp. In addition to commercializing these products, the company conducts research and development focused on expanding approved indications. Biofrontera sells its products directly to dermatology offices and groups using a buy-and-bill distribution model.
Company profile, executives and historyBiofrontera stock: common questions
What is Biofrontera's stock price?
BFRIW closed at $0.00 on Oct 30, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $0.55 and $1.66.
What is Biofrontera's market cap?
Biofrontera was worth $12.96M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is BFRIW's P/E ratio?
Biofrontera lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.60), so it has no meaningful P/E ratio.
How much revenue does Biofrontera make?
Biofrontera reported revenue of $46.18M for the twelve months to Jun 30, 2026, up 17.8% from a year earlier.
Does Biofrontera pay a dividend?
No. Biofrontera has not paid a cash dividend over the last twelve months.
When does Biofrontera report earnings next?
Biofrontera is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BFRIW stock performed over the past year?
Including dividends, BFRIW returned -99.0% over the past year, against +12.4% for the S&P 500.
Who are Biofrontera's competitors?
Companies most similar to Biofrontera by business, industry and size include VRCA, FBIO, DERM, OCUL, SIGA.